Season 2025 Episode 580
What happens when decades of lab expertise meet cutting-edge AI? In this interview, Dr. Jennifer Bath, President and CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), talks about how her team is using advanced science and artificial intelligence to develop safer, faster, and more effective antibody-based medicines.
With over 3,000 antibody discovery programs completed, they are transforming the future of drug discovery—cutting time, costs, and risks in the development process. Discover how decades of hands-on lab experience and innovative AI tools are helping identify the best drug candidates faster than ever before.
Learn more about ImmunoPrecise Antibodies: https://www.ipatherapeutics.com/
Watch the full YouTube interview here: https://youtu.be/mE9mDa7uGTs
And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1
Published on 7 months, 3 weeks ago
If you like Podbriefly.com, please consider donating to support the ongoing development.
Donate